3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
38
Melanoma
15
Neoplasm Metastasis
12
Squamous Cell Carcinoma of Head and Neck
11
Lung Neoplasms
11
Skin Neoplasms
10
Neoplasms
9
Ovarian Neoplasms
8
Recurrence
7
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Urinary Bladder Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma, Basal Cell
6
Breast Neoplasms
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Triple Negative Breast Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma, Merkel Cell
5
Carcinoma
5
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Mouth Neoplasms
4
Glioblastoma
4
Fallopian Tube Neoplasms
4
Stomach Neoplasms
3
Sarcoma
3
Mycosis Fungoides
3
Interventions
Cisplatin
6
pembrolizumab
5
Nivolumab
5
palbociclib
4
durvalumab
4
Pemetrexed
4
atezolizumab
3
abemaciclib
3
Fulvestrant
3
Carboplatin
3
Anastrozole
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
ribociclib
2
relatlimab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Radiosurgery
2
Paclitaxel
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Gemcitabine
2
Bevacizumab
2
AZD9833
2
trametinib
1
taletrectinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
cemiplimab
×
1 year
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled